Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

Brief description of study

The purpose of the study is to determine the safety and efficacy of the combination of Radium-223 dichloride and paclitaxel. We want to know if the combination of Radium-223 dichloride and paclitaxel can prolong progression-free survival (PFS) when compared to paclitaxel alone. Participants will be randomized into 1:1 to receive Radium-223 dichloride and paclitaxel or paclitaxel alone. The randomization procedure will stratify participants by hormone receptor status or presence of visceral metastasis.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.